The team used the AMG1541 LNP to deliver an mRNA influenza vaccine in mice. They compared this vaccine’s effectiveness to a flu vaccine made with the lipid SM-102, which is FDA-approved and was used ...

Approach that uses cell’s own strategy of liquid-liquid phase separation protects synthetic modifications from being washed away by the tide of cell growth.

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

Engineered human stomach organoids, transplanted into mice, produced insulin-secreting cells, offering a potential new ...

Abzena and Mabqi bring together two organizations that are focused on advancing antibody innovation through integration.

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.

Researchers analyzed the role of NUDT5 and its interaction with other proteins in the folate pathway and in regulating purine synthesis.

The data shows that downregulating PU.1 promotes the expression of immunoregulatory proteins on microglia that help protect cognitive function.

Triple therapy approach that hits cancer from multiple angles at once could be a game-changer against breast cancers that no longer respond to hormone treatment.

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.

The goal of the project is to develop novel approaches that strengthen and reduce the costs of domestic mAb biomanufacturing to protect against and treat infection by filoviruses.